Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Recombinant interferon alfa-2b may interfere with the growth of
cancer cells and slow the growth of kidney cancer. Giving celecoxib together with recombinant
interferon alpha-2b may kill more tumor cells and be an effective treatment for metastatic
kidney cancer.
PURPOSE: This phase II trial is studying how well giving celecoxib together with recombinant
interferon alfa-2b works in treating patients with metastatic kidney cancer who have
undergone surgery.